OmniAb, Inc. (OABI )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol OABI
- Company OmniAb, Inc.
- Price $3.08
- Changes Percentage 37.5
- Change 0.84
- Day Low $2.35
- Day High $3.12
- Year High $2.79
- Year Low $1.3
- Market Cap $234,012,899
- Price Avg 50 EMA (D) $2.33
- Price Avg 200 EMA (D) $1.88
- Exchange NASDAQ
- Volume 103,712
- Average Volume 710,157
- Open $2.35
- Previous Close $2.24
- EPS -0.46
- PE -4.27
- Earnings Announcement 2026-08-06 20:00:00
- Shares Outstanding $119,090,534
Company brief: OMNIAB, INC. (OABI )
- Healthcare
- Biotechnology
- Mr. Matthew W. Foehr
- https://www.omniab.com
- US
- N/A
- 09-30-2021
- US68218J1034
OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.